Challenges in the development and manufacturing of antibody-drug conjugates

Methods in Molecular Biology

Volumn 899, Issue , 2012, Pages 489-497

  Ducry, Laurent ^a  

^a LONZA AG   (Switzerland)

Author keywords

ADC; Antibody drug conjugate; Bioconjugate; Conjugation; Cytotoxic; Manufacturing; Process development

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PRODRUG;

ARTICLE; CHEMISTRY; CLINICAL TRIAL (TOPIC); HUMAN; METHODOLOGY; NEOPLASM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; NEOPLASMS; PRODRUGS;

EID: 84864133435     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-921-1_29     Document Type: Article

References (18)

1. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146
2. Ricart AD, Tolcher AW (2007) Technology insight: Cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 4:245-255
3. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154-169
4. Kratz F, Müller IA, Ryppa C, Warnecke A (2008) Prodrug strategies in anticancer chemotherapy. ChemMedChem 3:20-53
5. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235-244
6. Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 14:529-537
7. Mathé G, Loc TB, Bernhard J (1958) Effet sur la leucémie 1210 de la souris d'une combinaison par diazotation d'A- méthopérine et de -globulines de hamsters porteurs de cette leucémie par hétérogreffe. C R Hebd Seances Acad Sci 246(10):1626-1628
8. Ducry L, Stump B (2010) Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21:5-13
9. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with Trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
10. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi J-H, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA (2010) Phase I study of Trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704
11. Bartlett N, Forero-Torres A, Rosenblatt J, Fanale M, Horning SJ, Thompson S, Sievers EL, Kennedy DA (2009) Complete remissions with weekly dosing of SGN-35, a novel antibody- dug conjugate (ADC) targeting CD30, in phase I dose-Escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol 27:8500, Abstract
12. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888-897
13. DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK (2006) Antitumor ef ficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 12:242-249
14. DiJoseph JF, Khandke K, Dougher MM, Evans DY, Armellino DC, Hamann PR, Damle NK (2008) CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin. Hematology Meeting Reports 5:74-77
15. Wakankar AA, Feeney MB, Rivera J, Chen Y, Kim M, Sharma VK, Wang YJ (2010) Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: Changes due to modi fication and conjugation processes. Bioconjug Chem 21:1588-1595
16. Magalhães PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna TCV, Pessoa A Jr (2007) Methods of endotoxin removal from biological preparations: A review. J Pharm Sci 10:388-404
17. Wakankar A, Chen Y, Gokarn Y, Jacobson FS (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. mAbs 3:164-175
18. Stephan JP, Kozak KR, Wong WLT (2011) Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis 3:677-700